In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Ipamorelin | Synthetic analog CJC-1295 (with DAC) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 110 | 43 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (1 in people) | 2 (2 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 21 more mentions it but does not test it | 1 | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Ipamorelin | CJC-1295 (with DAC) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 293242 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| PharmacokineticsPharmacology | 1376 | 7151 |
|---|
| Bone and jointMusculoskeletal | 1515 | 11 |
|---|
| Body weightMetabolic and weight | 99 | 44 |
|---|
| Adverse eventsWhole body | 11 | 11 |
|---|
| Receptor activity and mechanismPharmacology | 312 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Ipamorelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
CJC-1295 (with DAC) differs from Somatorelin, human GHRH(1-44) at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Ipamorelin | CJC-1295 (with DAC) |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in d | No randomized trial result 13 results from other study designs. | 5.8 to 8.1 d Half-life · CJC-1295 28 d and 49 d trialsn not reported2006 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 87.5% Any treatment-emergent adverse event Placebo: 94.8% Dose studied: 0.03-mg/kg twice dailypostoperative day 1 to 7 or hospital dischargen = 1142014 | No comparable result |
No randomized trial result
13 results from other study designs.
5.8 to 8.1 d
Half-life · CJC-1295
28 d and 49 d trialsn not reported2006
87.5%
1 randomized-trial result measure it in another way or another unit.
Any treatment-emergent adverse event
Placebo: 94.8%
Dose studied: 0.03-mg/kg twice dailypostoperative day 1 to 7 or hospital dischargen = 1142014
No comparable result
1 randomized-trial result measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)
Helsinn Therapeutics (U.S.), Inc320 participantsApr 2011 to May 2014
Gastrointestinal Dysmotility
Helsinn Therapeutics (U.S.), Inc117 participantsApr 2008 to Dec 2009
Ileus
1 more mentions it but does not test it. They only measure it or name it in their text.
1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)
ConjuChem120 participantsDec 2005 to Sept 2006
Obesity · HIV Infections